rho GDP Dissociation Inhibitor (GDI) gamma (ARHGDIG) Peptid
ARHGDIG
Reaktivität: Säugetier
Wirt: Synthetic
BP, WB, IHC
-
- Target Alle ARHGDIG Produkte
- ARHGDIG (rho GDP Dissociation Inhibitor (GDI) gamma (ARHGDIG))
- Protein-Typ
- Synthetic
- Spezies
- Säugetier
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Sequenz
- DEAVPEYRAP GRKSLLEIRQ LDPDDRSLAK YKRVLLGPLP PAVDPSLPN
- Produktmerkmale
-
A synthetic peptide for use as a blocking control in assays to test for specificity of ARHGDIG antibody,
Alternative Names: ARHGDIG control peptide, ARHGDIG antibody Blocking Peptide, Anti-ARHGDIG Blocking Peptide, Rho Gdp Dissociation Inhibitor Blocking Peptide, Gdi Gamma Blocking Peptide
-
-
- Applikationshinweise
- Optimal conditions should be determined by the investigator
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handhabung
- Avoid repeated freeze/thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20 °C long term.
-
- Target
- ARHGDIG (rho GDP Dissociation Inhibitor (GDI) gamma (ARHGDIG))
- Hintergrund
- ARHGDIG is highly expressed in the entire brain, with regional variations. The mRNA is also present at high levels in kidney and pancreas and at moderate levels in spinal cord, stomach, and pituitary gland. ARHGDIG is mapped to chromosome band 16p13.3 which is rich in deletion mutants of genes involved in several human diseases, notably polycystic kidney disease, alpha-thalassemia, tuberous sclerosis, mental retardation, and cancer.
- Molekulargewicht
- 25 kDa
-
Sie sind hier:
